In December, The Medicine Maker will showcase the top technologies to have been released throughout 2020. Nominations are now open.

As the world grasps the severity of the ongoing pandemic, we must ask how we can accelerate vaccine development safely.

It is well accepted that vaccine development needs to move faster, but how can companies balance compliance and speed?

How are counterfeiters exploiting the COVID-19 pandemic to make a profit?

Harnessing the potential of microphysiological systems to advance drug discovery.

It is essential that drug development incorporates the patient view.

The FDA has approved its first biosimilar of 2020: Pfizer’s Nyvepria (pegfilgrastim-apgf).

There are ample opportunities for pharma companies to transition to greener chemical processes. Martin Hayes from Johnson Matthey tells us more.

How is the business of making medicine changing in light of the COVID-19 pandemic?

We need to optimize and then accelerate HPAPI drug product development. Alyn McNaughton from Lonza tells us more.